-5%
Clonazepam, the active ingredient in Pase, shares common pharmacological effects with benzodiazepines, including anticonvulsants, sedatives, muscle relaxants, and anxiolytic properties. These effects result from enhanced GABAergic neurotransmission at inhibitory synapses. Benzodiazepines increase the affinity of GABA receptors for the neurotransmitter, leading to greater chloride ion flux across the postsynaptic membrane.
Studies in animals indicate that clonazepam also affects serotonin levels. Additionally, electroencephalographic (EEG) research in humans has demonstrated that clonazepam rapidly suppresses various paroxysmal activities, such as spike-and-wave discharges in the absence of seizures, slow spike waves, generalized spikes, and irregular spike patterns. Its effects are more pronounced on generalized EEG abnormalities than focal abnormalities, making it beneficial for both generalized and focal epileptic conditions.
Pase is prescribed for the management of panic disorder, with or without agoraphobia. Panic disorder involves sudden, unexpected panic attacks along with persistent concern about experiencing further episodes or their potential consequences.
Additionally, Pase is used alone or alongside other treatments for Lennox-Gastaut Syndrome (petit mal variant), as well as akinetic and myoclonic seizures. It may also be considered for patients with absence seizures (petit mal) who have not responded to succinimides.
The long-term effectiveness of Pase beyond nine weeks has not been extensively studied in controlled clinical trials. Physicians prescribing Pase for extended periods should periodically assess its continued necessity and effectiveness.